Raines Douglas E, Claycomb Robert J, Forman Stuart A
Department of Anesthesia, Harvard Medical School, Boston, Massachusetts, USA.
Anesth Analg. 2003 Jan;96(1):112-8, table of contents. doi: 10.1097/00000539-200301000-00024.
At clinically relevant concentrations, ethers, alcohols, and halogenated alkanes enhance agonist action on the gamma-aminobutyric acid(A) (GABA(A)) receptor, whereas nonhalogenated alkanes do not. Many anesthetics also directly activate and/or inhibit GABA(A) receptors, actions that may produce important behavioral effects; although, the effects of nonhalogenated alkane anesthetics on GABA(A) receptor direct activation and inhibition have not been studied. In this study, we assessed the abilities of two representative nonhalogenated alkanes, cyclopropane and butane, to enhance agonist action, directly activate, and inhibit currents mediated by expressed alpha(1)beta(2)gamma(2L) GABA(A) receptors using electrophysiological techniques. Our studies reveal that cyclopro- pane and butane enhance agonist action on the GABA(A) receptor at concentrations that exceed those required to produce anesthesia. Neither nonhalogenated alkane directly activated nor inhibited GABA(A) receptors, even at concentrations that approach their aqueous saturated solubilities. These results strongly suggest that the behavioral actions of nonhalogenated alkane anesthetics do not result from their abilities to enhance agonist actions, directly activate, or inhibit alpha(1)beta(2)gamma(2L) GABA(A) receptors and are consistent with the hypothesis that electrostatic interactions between anesthetics and their protein binding sites modulate GABA(A) receptor potency.
When normalized to either their in vivo anesthetic potencies or hydrophobicities, cyclopropane and butane are 1-1.5 orders of magnitude less potent enhancers of agonist action on alpha(1beta2gamma2L) GABA(A) receptors than isoflurane. Additionally, cyclopropane and butane fail to directly activate or inhibit receptors, even at near aqueous saturating concentrations. Thus, it is unlikely that either enhancement or inhibition of the most common GABA(A) receptor subtype in the brain accounts for the behavioral activities of cyclopropane and butane.
在临床相关浓度下,醚类、醇类和卤代烷烃可增强激动剂对γ-氨基丁酸A(GABA(A))受体的作用,而非卤代烷烃则无此作用。许多麻醉剂也可直接激活和/或抑制GABA(A)受体,这些作用可能产生重要的行为效应;然而,非卤代烷烃麻醉剂对GABA(A)受体直接激活和抑制的作用尚未得到研究。在本研究中,我们使用电生理技术评估了两种代表性的非卤代烷烃环丙烷和丁烷增强激动剂作用、直接激活和抑制由表达的α(1)β(2)γ(2L) GABA(A)受体介导的电流的能力。我们的研究表明,环丙烷和丁烷在超过产生麻醉所需浓度时可增强对GABA(A)受体的激动剂作用。即使在接近其水饱和溶解度的浓度下,这两种非卤代烷烃也不会直接激活或抑制GABA(A)受体。这些结果强烈表明,非卤代烷烃麻醉剂的行为作用并非源于它们增强激动剂作用、直接激活或抑制α(1)β(2)γ(2L) GABA(A)受体的能力,这与麻醉剂与其蛋白质结合位点之间的静电相互作用调节GABA(A)受体效能的假设一致。
当以其体内麻醉效能或疏水性进行归一化时,环丙烷和丁烷作为激动剂对α(1β2γ2L) GABA(A)受体作用的增强剂,其效力比异氟烷低1 - 1.5个数量级。此外,即使在接近水饱和浓度时,环丙烷和丁烷也无法直接激活或抑制受体。因此,大脑中最常见的GABA(A)受体亚型的增强或抑制作用不太可能解释环丙烷和丁烷的行为活性。